What's happening
This bill requires health insurance plans in New York to cover at least two epinephrine auto-injectors per year with annual out-of-pocket costs capped at $100.
Why it matters
Improves access and affordability for life-saving medication. By capping out-of-pocket costs for epinephrine auto-injectors at $100 per year, the bill directly addresses high prices that can prevent people—especially those with severe allergies—from obtaining these essential emergency devices.
Reduces financial unpredictability for families and individuals. Regardless of deductible, copayment, or coinsurance, insured New Yorkers will know their maximum annual cost for epinephrine auto-injectors, making it easier to budget for healthcare needs and reducing the risk of going without due to cost.
Addresses coverage gaps across different insurance types. The bill’s language ensures these protections apply to individual, group, and blanket health insurance plans, as well as health savings account-qualified high-deductible plans (with adjustments for federal law), broadening the impact to most insured residents.
Potentially lowers public health risks. By increasing the likelihood that people at risk for life-threatening allergic reactions can afford and obtain epinephrine auto-injectors, the bill could reduce emergency room visits, severe health outcomes, and fatalities due to anaphylaxis.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Require Insurance for EpiPens
Plain English, a few words. Used as the page title.
Sponsors
History
- Approval memo.26
- Signed chap.553
- Delivered to governor
- Returned to senate
- Passed assembly
- Ordered to third reading rules cal.165
- Substituted for A6425A
- Referred to insurance
- Delivered to assembly
- Passed senateVote 61–0
- Advanced to third reading
- 2nd report cal.
Show 5 earlier actions
- 1st report cal.1254
- Print number 7114a
- Amend and recommit to insurance
- Referred to insurance
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Cover EpiPens With Insurance
Assembly Floor Calendar · Sponsor Daniel O'Donnell
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
7114--A
2023-2024 Regular Sessions
IN SENATE
May 18, 2023
Introduced by Sens. RIVERA, CLEARE, COONEY, GOUNARDES, HARCKHAM, JACK- SON, WEBB -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance -- recommitted to the Committee on Insurance in accordance with Senate Rule 6, sec. 8 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the insurance law, in relation to requiring health insurance plans to provide coverage for epinephrine auto-injector devices
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 39 to read as follows:
(39) (A) Every insurer issuing a policy of accident and health insurance delivered or issued for delivery in this state which provides major medical or similar comprehensive-type coverage shall include coverage for, at a minimum, two medically necessary epinephrine auto-injector devices for the emergency treatment of life-threatening allergic reactions. Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, the total amount that a covered person is required to pay out-of-pocket for such devices shall be capped at an amount not to exceed one hundred dollars annually regardless of the insured's deductible, copayment, coinsurance or any other cost-sharing requirement. If under federal law, application of this requirement would result in health savings account ineligibility under 26 USC 223, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of such a plan after the enrollee has satisfied the minimum deductible under 26 USC 223, except for with respect to items or
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD10597-03-4
services that are preventive care pursuant to 26 USC 223(c)(2)(C), in which case the requirements of this paragraph shall apply regardless of whether the minimum deductible under 26 USC 223 has been satisfied.
(B) For the purposes of this paragraph, "epinephrine auto-injector device" shall have the same meaning as provided in paragraph (b) of subdivision one of section three thousand-c of the public health law.
§ 2. Subsection (k) of section 3221 of the insurance law is amended by adding a new paragraph 23 to read as follows:
(23) (A) Every group or blanket policy of accident and health insurance delivered or issued for delivery in this state which provides medical coverage that includes coverage for physician services in a physician's office and every policy which provides major medical or similar comprehensive-type coverage shall provide coverage for, at a minimum, two medically necessary epinephrine auto-injector devices for the emergency treatment of life-threatening allergic reactions. Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, the total amount that a covered person is required to pay outof-pocket for such devices shall be capped at an amount not to exceed one hundred dollars annually regardless of the insured's deductible, copayment, coinsurance or any other cost-sharing requirement. If under federal law, application of this requirement would result in health savings account ineligibility under 26 USC 223, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of such a plan after the enrollee has satisfied the minimum deductible under 26 USC 223, except for with respect to items or services that are preventive care pursuant to 26 USC 223(c)(2)(C), in which case the requirements of this paragraph shall apply regardless of whether the minimum deductible under 26 USC 223 has been satisfied.
(B) For the purposes of this paragraph, "epinephrine auto-injector device" shall have the same meaning as provided in paragraph (b) of subdivision one of section three thousand-c of the public health law.
§ 3. Section 4303 of the insurance law is amended by adding a new subsection (vv) to read as follows:
(vv) (1) Every medical expense indemnity corporation, hospital service corporation and health service corporation which provides medical coverage that includes coverage for physician services in a physician's office and every policy which provides major medical or similar comprehensive-type coverage shall provide coverage for, at a minimum, two medically necessary epinephrine auto-injector devices for the emergency treatment of life-threatening allergic reactions. Such coverage may be subject to annual deductibles and coinsurance as may be deemed appropriate by the superintendent and as are consistent with those established for other benefits within a given policy; provided however, the total amount that a covered person is required to pay out-of-pocket for such devices shall be capped at an amount not to exceed one hundred dollars annually regardless of the insured's deductible, copayment, coinsurance or any other cost-sharing requirement. If under federal law, application of this requirement would result in health savings account ineligibility under 26 USC 223, this requirement shall apply for health savings account-qualified high deductible health plans with respect to the deductible of such a plan after the enrollee has satisfied the minimum deductible under 26 USC 223, except for with respect to items or services that are preventive care pursuant to 26 USC 223(c)(2)(C), in which case the requirements of this paragraph shall apply regardless of whether the minimum deductible under 26 USC 223 has been satisfied.
(2) For the purposes of this subsection, "epinephrine auto-injector device" shall have the same meaning as provided in paragraph (b) of subdivision one of section three thousand-c of the public health law.
§ 4. This act shall take effect January 1, 2026 and shall apply to all policies and contracts issued, renewed, modified, altered or amended on or after such date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law, in relation to requiring health insurance plans to provide coverage for epinephrine auto-injector devices
Purpose or general idea of bill
To require insurance coverage for epinephrine auto-injectors ("epipens") and set an annual cost-sharing cap.
Summary of provisions
Section 1 amends subsection (i) of section 3216 of the insurance law, as it relates to individual accident and health insurance policy provisions, by adding a new paragraph 39 to require insurance coverage of epinephrine auto-injectors. The language includes an exemption for certain high deductible plans to comply with federal law.
Section 2 amends subsection (k) of section 3221, as it relates to group or blanket accident and health insurance policies of the insurance law, by adding a new paragraph 23 that provides coverage requirements and a maximum copayment of $100 annually for two epinephrine auto-injector devices. The language includes an exemption for certain high deductible plans to comply with federal law.
Section 3 amends section 4303 of the insurance law by adding a new subsection (vv) to provide coverage requirements and maximum copayment. The language includes an exemption for certain high deductible plans to comply with federal law.
Section 4 provides the effective date.
Justification
The rising cost of an epinephrine auto-injector, or "epi-pen," has far outpaced inflation in recent years. Without mandated coverage and a reasonable cost-sharing cap, the accessibility of these life-saving devices are beyond the means of millions of New Yorkers.
In 2010, the most common price for a two-pack of epi-pens was approxi- mately $100. Today, the generic version will almost always cost upwards of $350 and the brand name can cost upwards of $700. It is unacceptable that so many people are forced to risk not having the device during a life-threatening emergency due to the prohibitive cost.
Separate studies by the National Institutes of Health (NIH) and Blue Cross Blue Shield showed that emergency room visits by children having serious anaphylactic reactions have more than doubled during the 2010s, the same timeframe during which epi-pen prices began to skyrocket. An epinephrine auto-injector significantly mitigates the risk of death from a serious allergic reaction.
By mandating insurance plans to provide coverage for epi-pens and capping the annual cost at $100 for two pens, these life-saving devices
will be more widely accessible for those who need them. Access to essential medication should not be contingent on income level.
Prior legislative history
New Bill.
Fiscal implications for state and local governments
None.
Effective date
Immediately
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.